Global health governance must depend less on FDA, Pg13

Key Highlights:

• The US FDA has been a globally influential regulatory authority for medicines, vaccines, medical devices, and diagnostics for decades.
• Many countries rely on FDA approvals to shorten their own review timelines for new technologies.
• Recent leadership turnover, budget pressures, and structural reforms within the FDA have caused turbulence.
• The instability highlights the need to reduce over-reliance on a single regulatory authority like the FDA.
• Countries like India are strengthening their own regulatory capacity to reduce dependence on the FDA.

Detailed Insights:

• The FDA's regulatory requirements have historically set the benchmark for international quality expectations in drug manufacturing and medical devices.
• Changes in FDA policies for digital health tools, AI in healthcare, and clinical-decision support systems are being closely watched globally.
• Leadership transitions at critical FDA centers create uncertainty about regulatory priorities, especially for vaccines, gene therapy, and cell-based treatments.
• The Central Drugs Standard Control Organisation (CDSCO) in India is strengthening its capacity, reducing reliance on the FDA.
• A broader shift in global health governance is needed, balancing reliance on established regulators with stronger regional and national capacities.

Key Concepts Involved:

• FDA: The US Food and Drug Administration, a regulatory agency responsible for the safety of food, drugs, and medical devices.
• CDSCO: India's Central Drugs Standard Control Organisation, responsible for regulating pharmaceuticals and medical devices.
• Global Health Governance: The collective mechanisms and processes through which global health issues are managed and addressed.